• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evolving Indications for Liver Transplantation for Hepatocellular Carcinoma Following the Milan Criteria.米兰标准之后肝细胞癌肝移植的不断变化的适应证
Cancers (Basel). 2025 Feb 3;17(3):507. doi: 10.3390/cancers17030507.
2
Preoperative assessment of microvascular invasion risk using gadoxetate-enhanced MRI for predicting outcomes after liver transplantation for single hepatocellular carcinoma within the Milan criteria.使用钆塞酸增强 MRI 对米兰标准内单个肝细胞癌进行术前微血管侵犯风险评估,以预测肝移植术后的结局。
Eur Radiol. 2024 Jan;34(1):498-508. doi: 10.1007/s00330-023-09936-y. Epub 2023 Jul 28.
3
Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria.米兰标准内分类的肝细胞癌微血管侵犯的潜在预测因素。
Int J Clin Oncol. 2018 Feb;23(1):98-103. doi: 10.1007/s10147-017-1189-8. Epub 2017 Sep 5.
4
International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.肝细胞癌超出米兰标准的肝移植局部区域治疗结局的国际研究。
JHEP Rep. 2021 Jul 13;3(5):100331. doi: 10.1016/j.jhepr.2021.100331. eCollection 2021 Oct.
5
Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma.预测肝细胞癌肝移植受者的微血管侵犯
Cureus. 2024 Dec 2;16(12):e75007. doi: 10.7759/cureus.75007. eCollection 2024 Dec.
6
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
7
Liver resection versus liver transplantation for hepatocellular carcinoma within the Milan criteria based on estimated microvascular invasion risks.基于估计的微血管侵犯风险,对米兰标准内的肝细胞癌进行肝切除与肝移植的比较
Gastroenterol Rep (Oxf). 2023 Jun 26;11:goad035. doi: 10.1093/gastro/goad035. eCollection 2023.
8
[Association of microvascular invasion with recurrence and prognosis of patients with small hepatocellular carcinoma undergoing liver transplantation].[微血管侵犯与接受肝移植的小肝细胞癌患者复发及预后的相关性]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Nov;43(6):658-63. doi: 10.3785/j.issn.1008-9292.2014.11.004.
9
Liver transplantation for hepatocellular carcinoma: a proposal for including preoperative serological indicators improves the Milan criteria expanded.肝细胞癌的肝移植:一项纳入术前血清学指标以改进扩大的米兰标准的提议。
Transl Gastroenterol Hepatol. 2024 Oct 14;9:63. doi: 10.21037/tgh-24-40. eCollection 2024.
10
Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.甲胎蛋白调整至肝癌大小标准与肝癌肝移植后的良好生存相关。
United European Gastroenterol J. 2021 Mar;9(2):209-219. doi: 10.1177/2050640620948665. Epub 2021 Feb 10.

本文引用的文献

1
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.欧洲肝脏研究学会肝细胞癌管理临床实践指南
J Hepatol. 2025 Feb;82(2):315-374. doi: 10.1016/j.jhep.2024.08.028. Epub 2024 Dec 17.
2
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.2024年亚太肝脏研究学会肝细胞癌全身治疗临床实践指南
Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.
3
Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?肝移植后肝细胞癌复发的临床决策相关挑战:有希望吗?
World J Transplant. 2024 Sep 18;14(3):96637. doi: 10.5500/wjt.v14.i3.96637.
4
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.肝移植前接受免疫治疗的肝细胞癌患者的意向性分析结果:多中心VITALITY研究
J Hepatol. 2025 Mar;82(3):512-522. doi: 10.1016/j.jhep.2024.09.003. Epub 2024 Sep 8.
5
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.肝切除术后肝细胞癌侵袭性复发的组织学预测因子。
J Hepatol. 2024 Dec;81(6):995-1004. doi: 10.1016/j.jhep.2024.06.018. Epub 2024 Jun 24.
6
Preoperative Prediction of Microvascular Invasion with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Patients with Single Hepatocellular Carcinoma: The Implication of Surgical Decision on the Extent of Liver Resection.钆塞酸二钠增强磁共振成像对单发肝细胞癌患者微血管侵犯的术前预测:肝切除范围手术决策的意义
Liver Cancer. 2023 Jul 7;13(2):181-192. doi: 10.1159/000531786. eCollection 2024 Apr.
7
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌预防、诊断和治疗实践指南。
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
8
Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria.肝细胞癌的肝移植:移植标准的历史演变
World J Clin Cases. 2022 Oct 16;10(29):10413-10427. doi: 10.12998/wjcc.v10.i29.10413.
9
Radiomics for the detection of microvascular invasion in hepatocellular carcinoma.基于影像组学的肝细胞癌微血管侵犯检测
World J Gastroenterol. 2022 May 28;28(20):2176-2183. doi: 10.3748/wjg.v28.i20.2176.
10
Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.终末期肝病模型(MELD)评分30分分配政策对意大利肝移植结局的影响。
J Hepatol. 2022 Mar;76(3):619-627. doi: 10.1016/j.jhep.2021.10.024. Epub 2021 Nov 10.

米兰标准之后肝细胞癌肝移植的不断变化的适应证

Evolving Indications for Liver Transplantation for Hepatocellular Carcinoma Following the Milan Criteria.

作者信息

Kokudo Takashi, Kokudo Norihiro

机构信息

National Center for Global Health and Medicine, Tokyo 162-8655, Japan.

出版信息

Cancers (Basel). 2025 Feb 3;17(3):507. doi: 10.3390/cancers17030507.

DOI:10.3390/cancers17030507
PMID:39941874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11815920/
Abstract

Since their introduction in the 1990s, the Milan criteria have been the gold standard of indication for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Nevertheless, several institutions have reported wider indication criteria for LT with comparable survival outcomes. This paper summarizes the recent indications for LT for HCC through a literature review. There are several criteria expanding the Milan criteria, which can be subdivided into the "based on tumor number and size only", "based on tumor number and size plus tumor markers", and "based on tumor differentiation" groups, with the outcomes being comparable to those of patients included within the Milan criteria. Besides the tumor size and number, which are included in the Milan criteria, recent criteria included biomarkers and tumor differentiation. Several retrospective studies have reported microvascular invasion (MVI) as a significant risk factor for postoperative recurrence, highlighting the importance of preoperatively predicting MVI. Several studies attempted to identify preoperative predictive factors for MVI using tumor markers or preoperative imaging findings. Patients with HCC who are LT candidates are often treated while on the waiting list to prevent the progression of HCC or to reduce the measurable disease burden of HCC. The expanding repertoire of chemotherapeutic regiments suitable for patients with HCC should be further investigated. : There are several criteria expanding Milan criteria, with the outcomes being comparable to those of patients included within the Milan criteria.

摘要

自20世纪90年代引入以来,米兰标准一直是肝细胞癌(HCC)患者肝移植(LT)的金标准适应证。然而,一些机构报告了更宽松的LT适应证标准,且生存结果相当。本文通过文献综述总结了近期HCC的LT适应证。有几个标准扩展了米兰标准,可分为“仅基于肿瘤数量和大小”、“基于肿瘤数量和大小加肿瘤标志物”以及“基于肿瘤分化”组,其结果与米兰标准所涵盖患者的结果相当。除了米兰标准中包含的肿瘤大小和数量外,近期标准还纳入了生物标志物和肿瘤分化。几项回顾性研究报告称微血管侵犯(MVI)是术后复发的重要危险因素,凸显了术前预测MVI的重要性。几项研究试图使用肿瘤标志物或术前影像学检查结果来识别MVI的术前预测因素。作为LT候选者的HCC患者在等待名单上时通常会接受治疗,以防止HCC进展或减轻可测量的HCC疾病负担。适合HCC患者的化疗方案不断增加,对此应进一步研究。:有几个标准扩展了米兰标准,其结果与米兰标准所涵盖患者的结果相当。